Trials / Completed
CompletedNCT06246695
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study was to assess the effect of rifampicin and itraconazole, on the pharmacokinetics (PK) of Jaktinib in healthy Volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib Hydrochloride Tablets | Oral Jaktinib 100 mg for 1 day |
| DRUG | Itraconazole capsule | Oral Itraconazole 200 mg for 9 day |
| DRUG | Rifampicin Capsules | Oral Rifampicin 600 mg for 11 day |
Timeline
- Start date
- 2021-10-27
- Primary completion
- 2022-01-12
- Completion
- 2022-01-12
- First posted
- 2024-02-07
- Last updated
- 2024-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06246695. Inclusion in this directory is not an endorsement.